Abivax SA - Asset Resilience Ratio

Latest as of December 2025: 2.34%

Abivax SA (ABVX) has an Asset Resilience Ratio of 2.34% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€13.70 Million

≈ $16.01 Million USD Cash + Short-term Investments

Total Assets

€584.34 Million

≈ $683.16 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Abivax SA's Asset Resilience Ratio has changed over time. Check Abivax SA strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Abivax SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ABVX market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€13.70 Million	2.34%
Total Liquid Assets	€13.70 Million	2.34%

Asset Resilience Insights

Limited Liquidity: Abivax SA maintains only 2.34% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Abivax SA Industry Peers by Asset Resilience Ratio

Compare Abivax SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Sk Biopharmaceuticals Co Ltd KO:326030	Biotechnology	0.14%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Theravance Biopharma Inc F:0TB	Biotechnology	37.29%

Annual Asset Resilience Ratio for Abivax SA (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Abivax SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.34%	€13.70 Million ≈ $16.01 Million	€584.34 Million ≈ $683.16 Million	-40.24pp
2024-12-31	42.59%	€87.40 Million ≈ $102.18 Million	€205.23 Million ≈ $239.93 Million	+34.28pp
2023-12-31	8.30%	€27.16 Million ≈ $31.75 Million	€327.06 Million ≈ $382.37 Million	+8.29pp
2022-12-31	0.02%	€12.00K ≈ $14.03K	€73.35 Million ≈ $85.76 Million	+0.01pp
2021-12-31	0.01%	€12.00K ≈ $14.03K	€110.36 Million ≈ $129.03 Million	-0.01pp
2020-12-31	0.02%	€12.00K ≈ $14.03K	€71.30 Million ≈ $83.35 Million	-0.01pp
2019-12-31	0.02%	€12.00K ≈ $14.03K	€51.73 Million ≈ $60.48 Million	-18.50pp
2018-12-31	18.52%	€10.01 Million ≈ $11.71 Million	€54.05 Million ≈ $63.19 Million	-37.78pp
2017-12-31	56.31%	€30.30 Million ≈ $35.43 Million	€53.81 Million ≈ $62.92 Million	+6.64pp
2016-12-31	49.67%	€30.10 Million ≈ $35.19 Million	€60.60 Million ≈ $70.84 Million	-1.47pp
2015-12-31	51.15%	€39.01 Million ≈ $45.60 Million	€76.27 Million ≈ $89.17 Million	+46.66pp
2014-12-31	4.49%	€1.70 Million ≈ $1.99 Million	€37.97 Million ≈ $44.39 Million	+3.45pp
2013-12-31	1.04%	€400.00K ≈ $467.64K	€38.46 Million ≈ $44.97 Million	--

pp = percentage points

About Abivax SA

PA:ABVX France Biotechnology

Market Cap

$10.08 Billion

€8.62 Billion EUR

Market Cap Rank

#2552 Global

#53 in France

Share Price

€108.70

Change (1 day)

+1.30%

52-Week Range

€58.80 - €135.00

All Time High

€135.00